Skip to content

Transradial Versus Transulnar Artery Approach for Coronary Interventions

A Randomized Study of Transradial Versus Transulnar Artery Approach for Coronary Interventions

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01364532
Acronym
AURA
Enrollment
572
Registered
2011-06-02
Start date
2011-04-30
Completion date
2011-09-30
Last updated
2011-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Access in Percutaneous Coronary Angiography or Intervention

Keywords

transulnar arterial access, transradial arterial access, percutaneous coronary intervention

Brief summary

The transradial route is increasingly used as an access site in percutaneous coronary interventions, as it is considered equivalent to transfemoral approach in terms of efficacy but with a decreased vascular complication risk. Information concerning the efficacy and safety of transulnar approach is sparse. This is a prospective, randomized, investigator-initiated study to compare transradial versus transulnar approach as a default strategy for coronary angiography, ad-hoc or elective percutaneous coronary intervention (PCI). Consecutive eligible patients with an indication for coronary angiography, will be randomized after written informed consent in a 1:1 ratio to either transradial or transulnar access. Assessment of angiographic and procedural characteristics(including amount of contrast medium, arterial access, fluoroscopy and procedural time), as well as any vascular or other peri-procedural complications of the cases enrolled, will be performed. After hospital discharge, all patients will return at Day 60 ±5 days for Doppler ultrasound assessment of the forearm vessels and documentation of major adverse cardiovascular events (defined as death, myocardial infarction, target vessel revascularization and stroke. Coronary angiography patients will be additionally randomized in a 1:1 ratio to either 2500 or 5000 IU of unfractioned heparin.

Interventions

PROCEDURETransulnar arterial access

Transulnar arterial access in coronary angiography, ad-hoc or elective PCI

PROCEDURETransradial arterial access

Transradial arterial access for coronary angiography,ad-hoc or elective PCI

Sponsors

University of Patras
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age\>18 years * Plan for Coro- and ad hoc PCI, if necessary * Written informed consent

Exclusion criteria

* Cardiogenic shock, haemodynamic instability, Killip class III * Chronic hemodialysis * Coronary artery bypass grafting (CABG) with either bilateral internal mammary artery (IMA) or bilateral radial artery use

Design outcomes

Primary

MeasureTime frameDescription
Successful arterial access free from need for crossover and free from vascular or coronary ischemic complications (MACEs)within 60± daysThe primary end point will be assessed within 60±5 days after randomizationMACEs are considered both vascular and coronary ischemic complications. Vascular complications include arterial occlusion, local arterial perforation, compartment syndrome, pseudoaneurysm, fistula formation, major bleeding, hematoma of at least 10cm length, or any vascular damage requiring prolonged hospitalization or intervention. Coronary ishcemic complications include cardiac death, non fatal myocardial infarction, urgent repeat revascularization and stroke.

Secondary

MeasureTime frameDescription
Fluoroscopy timeFluoroscopy time will be assessed within 1 minute after the end of coronary angiography or coronary interventionFluoroscopy time (in seconds) assessed within 1 minute after the end of coronary angiography or coronary intervention
Amount of contrast mediumThe amount of contrast medium will be assessed within 1 minute after the end of coronary angiography or coronary interventionVolume of contrast medium (ml) will be assessed within 1 minute after the end of coronary angiography or coronary intervention
Vascular complication defined as post-procedural occlusion, perforation, pseudo-aneurysm, fistula or hematoma formationVascular complication will be assessed 6 hours after the end of coronary angiography or interventionVascular complication (defined as post-procedural occlusion, perforation, pseudo-aneurysm, fistula or hematoma formation of at least 10 cm length, compartment syndrome) will be assessed 6 hours after the end of coronary angiography or intervention
Procedural duration (defined as the sum of arterial access, coronary angiography and coronary intervention duration)Procedural duration will be assessed within 1 minute after the end of coronary angiography or coronary interventionProcedural duration (defined as the sum of arterial access, coronary angiography and coronary intervention duration)will be assessed within 1 minute after the end of coronary angiography or coronary intervention

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026